News | December 31, 2023
Alkem completes sale of St. Louis manufacturing facility for US$ 7.96 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
The initiative will focus on advocating for cleaner air
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Subscribe To Our Newsletter & Stay Updated
